SER
Income statement / Annual
Last year (2023), Serina Therapeutics Inc's total revenue was $142,000.00,
a decrease of 71.60% from the previous year.
In 2023, Serina Therapeutics Inc's net income was -$14.80 M.
See Serina Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$142,000.00
|
$500,000.00
|
$3.04 M
|
$54,000.00
|
$1.73 M
|
$1.40 M
|
$1.40 M
|
$1.67 M
|
| Cost of Revenue |
$171,000.00 |
$145,000.00 |
$150,000.00 |
$1.28 M |
$998,500.00 |
$841,000.00 |
$685,000.00 |
$911,000.00 |
| Gross Profit |
-$29,000.00 |
$355,000.00 |
$2.89 M |
-$1.23 M |
$729,500.00 |
$555,000.00 |
$719,000.00 |
$755,000.00 |
| Gross Profit Ratio |
-0.2 |
0.71 |
0.95 |
-22.72 |
0.42 |
0.4 |
0.51 |
0.45 |
| Research and Development
Expenses |
$603,000.00
|
$1.57 M
|
$3.80 M
|
$3.58 M
|
$5.35 M
|
$5.35 M
|
$5.27 M
|
$7.87 M
|
| General & Administrative
Expenses |
$0.00
|
$1.29 M
|
$1.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$9.33 M
|
$1.29 M
|
$1.30 M
|
$5.60 M
|
$7.94 M
|
$5.65 M
|
$3.87 M
|
$5.62 M
|
| Other Expenses |
$0.00 |
-$265,916.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$9.93 M |
$2.77 M |
$4.67 M |
$9.18 M |
$13.29 M |
$11.00 M |
$9.14 M |
$13.49 M |
| Cost And Expenses |
$10.10 M |
$2.77 M |
$4.67 M |
$10.46 M |
$14.29 M |
$11.84 M |
$9.82 M |
$14.41 M |
| Interest Income |
$0.00 |
$1,757.00 |
$10,859.00 |
$0.00 |
$29,000.00 |
$116,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$4.90 M |
$15,878.00 |
$3,094.00 |
$404,000.00 |
$0.00 |
$0.00 |
$12,000.00 |
$25,000.00 |
| Depreciation &
Amortization |
$131,000.00
|
$132,000.00
|
$131,000.00
|
$1.26 M
|
$951,000.00
|
$535,000.00
|
$682,000.00
|
$845,000.00
|
| EBITDA |
-$9.78 M
|
-$2.60 M
|
-$1.59 M
|
-$8.74 M
|
-$11.61 M
|
-$7.20 M
|
-$7.74 M
|
-$11.89 M
|
| EBITDA Ratio |
-68.87 |
-4.95 |
-0.52 |
-169.48 |
-6.72 |
-7.1 |
-5.51 |
-7.14 |
| Operating Income Ratio
|
-70.14
|
-4.54
|
-0.54
|
-192.72
|
-7.27
|
-7.48
|
-6
|
-7.65
|
| Total Other
Income/Expenses Net |
-$4.85 M
|
-$411,740.00
|
$366,805.00
|
$8,000.00
|
$323,000.00
|
$2.71 M
|
$1.78 M
|
-$4.62 M
|
| Income Before Tax |
-$14.81 M |
-$2.68 M |
-$1.26 M |
-$10.40 M |
-$12.24 M |
-$7.73 M |
-$6.64 M |
-$17.36 M |
| Income Before Tax Ratio
|
-104.3
|
-5.36
|
-0.42
|
-192.57
|
-7.08
|
-5.54
|
-4.73
|
-10.42
|
| Income Tax Expense |
-$8,000.00 |
-$250,038.00 |
$3,094.00 |
$466,000.00 |
$148,000.00 |
-$229,000.00 |
-$57,000.00 |
-$1.86 M |
| Net Income |
-$14.80 M |
-$2.68 M |
-$1.26 M |
-$10.87 M |
-$12.15 M |
-$7.50 M |
-$6.58 M |
-$15.49 M |
| Net Income Ratio |
-104.25 |
-5.36 |
-0.42 |
-201.2 |
-7.03 |
-5.37 |
-4.69 |
-9.3 |
| EPS |
-13.72 |
-2.49 |
-1.17 |
-10.14 |
-11.47 |
-7.56 |
-6.46 |
-15.21 |
| EPS Diluted |
-13.72 |
-2.49 |
-1.17 |
-10.14 |
-11.47 |
-7.56 |
-6.46 |
-15.21 |
| Weighted Average Shares
Out |
$1.08 M
|
$1.08 M
|
$1.08 M
|
$1.07 M
|
$1.06 M
|
$992,721.00
|
$1.02 M
|
$1.02 M
|
| Weighted Average Shares
Out Diluted |
$1.08 M
|
$1.08 M
|
$1.08 M
|
$1.07 M
|
$1.06 M
|
$992,721.00
|
$1.02 M
|
$1.02 M
|
| Link |
|
|
|
|
|
|
|
|
